Major Pandemic Relief Ends In September
September is when a lot of COVID-19 relief expires. By the end of this month, millions of Americans relying on the emergency aid programs to make ends meet will have to do without, as funding for major programs like federal unemployment insurance and subsidized health care for the unemployed runs dry. On Monday Sept. 6, […]
One Month of DAPT Reasonable in Patients at High Bleeding Risk
Dual antiplatelet therapy (DAPT) for 1 month after percutaneous coronary intervention (PCI) lowered bleeding rates and was non-inferior for ischemic events compared with 3-month DAPT in patients at high bleeding risk, according to results of the MASTER DAPT trial. Among the 4,579 patients in the intention-to-treat (ITT) population, major or clinically relevant non-major bleeding occurred […]
Alzheimer’s Aducanumab Prescribing Information Changes
Just a month after it gave the new Alzheimer’s drug aducanumab (Aduhelm) the green light, the FDA decided to change the label. The agency approved an updated label narrowing who should receive the drug, stating that aducanumab should be initiated in Alzheimer’s patients with “mild cognitive impairment or mild dementia stage of disease, the population […]